Krebs Biochemicals & Industries Limited (KREBSBIO.NS)
- Previous Close
90.01 - Open
88.00 - Bid --
- Ask --
- Day's Range
86.34 - 89.90 - 52 Week Range
66.12 - 129.07 - Volume
13,058 - Avg. Volume
24,483 - Market Cap (intraday)
1.901B - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
-- - EPS (TTM)
-12.49 - Earnings Date Aug 5, 2025 - Aug 9, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date Sep 14, 2005
- 1y Target Est
--
Krebs Biochemicals & Industries Limited engages in the manufacture and sale of active pharmaceutical ingredients in India. The company develops biotech processes for application in medicine, agriculture, and industry. Its products include androstenedione, lovastatin, and simvastatin, which are used for anti-cholesterol and steroid intermediate applications. The company also develops various products, including amlodipine, cetirizine, orlistat, serratiopepetidase, telmisartan, and phenylephrine for anti-hypertension, anti-histamine, anti-obesity, anti-inflammatory, and cold and cough applications. In addition, it offers contract manufacturing services for large pharmaceutical and multinational companies. The company was incorporated in 1991 and is based in Visakhapatnam, India.
krebsbiochem.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: KREBSBIO.NS
View MorePerformance Overview: KREBSBIO.NS
Trailing total returns as of 6/13/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KREBSBIO.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KREBSBIO.NS
View MoreValuation Measures
Market Cap
1.90B
Enterprise Value
4.02B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.37
Price/Book (mrq)
--
Enterprise Value/Revenue
9.28
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-62.20%
Return on Assets (ttm)
-7.56%
Return on Equity (ttm)
--
Revenue (ttm)
433.12M
Net Income Avi to Common (ttm)
-269.39M
Diluted EPS (ttm)
-12.49
Balance Sheet and Cash Flow
Total Cash (mrq)
1.42M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-56.05M